	US 12,215,356 B2
	Methods of preparing a primary cell sample
Lance Gavin Laing, Orono, MN (US); Ben Rich, Minneapolis, MN (US); and Abhijit Dandapat, Minneapolis, MN (US)
Assigned to Celcuity Inc., Minneapolis, MN (US)
Filed by Celcuity Inc., Minneapolis, MN (US)
Filed on Jan. 23, 2023, as Appl. No. 18/100,437.
Application 18/100,437 is a continuation of application No. 15/950,739, filed on Apr. 11, 2018, granted, now 11,591,573.
Application 15/950,739 is a continuation of application No. PCT/US2016/057923, filed on Oct. 20, 2016.
Claims priority of provisional application 62/243,765, filed on Oct. 20, 2015.
Prior Publication US 2023/0235293 A1, Jul. 27, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/09 (2010.01); C12N 5/00 (2006.01); C12N 5/07 (2010.01)

CPC C12N 5/0693 (2013.01) [C12N 5/0018 (2013.01); C12N 5/06 (2013.01); C12N 2500/02 (2013.01); C12N 2501/48 (2013.01); C12N 2501/727 (2013.01); C12N 2501/734 (2013.01); C12N 2503/00 (2013.01); C12N 2533/52 (2013.01); C12N 2533/54 (2013.01); C12N 2533/90 (2013.01)]

10 Claims

1. A method of increasing the cell count and cell colony size of viable cancer cells obtained from a human, the method comprising:

culturing the viable cancer cells obtained from the human subject in a medium comprising at least one caspase inhibitor, at least one MMP3 inhibitor and at least one Rho-associated kinase inhibitor under conditions comprising greater than 2% and less than 20% oxygen for at least 24 hours; and

attaching the cultured cancer cells to a surface comprising a hydrated and folded extracellular matrix (ECM).